Biomea Fusion, Inc. (BMEA)

Biomea Fusion shares fell 11.27% to close at $1.26 after the company announced Phase 1 clinical trial results for its oral GLP-1 candidate BMF-650. While the company reported consistent weight reduction and encouraging tolerability, analysts noted that the weight loss results remain preliminary, with longer-term trials and toxicology studies still outstanding. The mixed reception to the data, combining early positive efficacy signals with caution about the need for more comprehensive studies, drove the stock lower on heavy volume of over 4.2 million shares.

Biomea Fusion announced it will report results from its Phase I GLP-131 clinical study evaluating BMF-650, an investigational next-gen oral small-molecule GLP-1 receptor agonist, on October 13, 2026. Despite this bullish news, BMEA shares closed at $1.36, down 5.56% from the open of $1.44, with the stock trading in a range of $1.36 to $1.46 on volume of 694,830. The upcoming data readout for BMF-650 could serve as a significant catalyst for the stock, though today's price action suggests investors may be taking profits or awaiting further clarity. The direction signal from the news is positive, but the market's immediate reaction was negative.